Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/ pharmacodynamic model: Exploring the seesaw effect"

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2664-2668

  Werth, Brian J ^a   Steed, Molly E ^a   Kaatz, Glenn W ^b,c,d   Rybak, Michael J ^a,b,c  

^a Anti Infective Research Laboratory   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 2; PENICILLIN BINDING PROTEIN 4; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PENICILLIN-BINDING PROTEINS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84877855965     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02308-12     Document Type: Article

References (21)

1. Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S. 2008. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: Potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J. Am. Chem. Soc. 130:9212-9213.
2. Steed ME, Rybak MJ. 2010. Ceftaroline: A new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy 30:375-389.
3. Kosowska-Shick K, McGhee PL, Appelbaum PC. 2010. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 54:1670-1677.
4. Moisan H, Pruneau M, Malouin F. 2010. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J. Antimicrob. Chemother. 65:713-716.
5. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. 2005. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. 49:3501-3512.
6. Saravolatz L, Pawlak J, Johnson L. 2010. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycinintermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54:3027-3030.
7. Vidaillac C, Leonard SN, Rybak MJ. 2009. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53:4712-4717.
8. Steed M, Vidaillac C, Rybak MJ. 2011. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillinresistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 55:3522-3526.
9. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal β-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillinresistant Staphylococcus aureus: Role of enhanced daptomycin binding. Clin. Infect. Dis. 53:158-163.
10. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, Richardson P, Bruce D, Rubin E, Myers E, Siggia ED, Tomasz A. 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U. S. A. 104:9451-9456.
11. Finan JE, Archer GL, Pucci MJ, Climo MW. 2001. Role of penicillinbinding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:3070-3075.
12. Sieradzki K, Pinho MG, Tomasz A. 1999. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J. Biol. Chem. 274:18942-18946.
13. Sieradzki K, Tomasz A. 1999. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J. Bacteriol. 181:7566-7570.
14. Pieper R, Gatlin-Bunai CL, Mongodin EF, Parmar PP, Huang ST, Clark DJ, Fleischmann RD, Gill SR, Peterson SN. 2006. Comparative proteomic analysis of Staphylococcus aureus strains with differences in resistance to the cell wall-targeting antibiotic vancomycin. Proteomics 6:4246-4258.
15. Boyle-Vavra S, Yin S, Challapalli M, Daum RS. 2003. Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin. Antimicrob. Agents Chemother. 47:1028-1036.
16. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.
17. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. 2013. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycinintermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 57:66-73.
19. DeMarco CE, Cushing LA, Frempong-Manso E, Seo SM, Jaravaza TA, Kaatz GW. 2007. Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 51:3235-3239.
20. Shlaes DM, Shlaes JH, Vincent S, Etter L, Fey PD, Goering RV. 1993. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrob. Agents Chemother. 37:2432-2437.
21. Moreira B, Boyle-Vavra S, deJonge BL, Daum RS. 1997. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1788-1793.